MINNEAPOLIS, Aug. 8 /PRNewswire-FirstCall/ -- MedicalCV, Inc. (OTC:MDCV) (BULLETIN BOARD: MDCV) , http://www.medcvinc.com/, a cardiovascular surgery device manufacturer, announced today that its Board of Directors elected Larry G. Haimovitch and J. Robert Paulson, Jr. as new directors, effective August 3, 2005. Mr. Haimovitch is President of Haimovitch Medical Technology Consultants, a San Francisco-based health care consulting firm he formed in 1990. His firm, whose current area of emphasis includes minimally invasive surgical technologies, specializes in the analysis of the medical device industry with emphasis on the current trends and future outlook for emerging medical technology. Mr. Paulson is President, Chief Executive Officer and a director of Restore Medical, Inc., a company focused on developing and marketing products for the ear, nose and throat field. Prior to joining Restore Medical in April 2005, Mr. Paulson served as Chief Financial Officer and Vice President of Marketing for Endocardial Solutions, Inc. from August 2002 until St. Jude Medical acquired Endocardial Solutions in March 2005. From 2001 to June 2002, Mr. Paulson was Senior Vice President and General Manager of the Auditory Division of Advanced Bionics Corporation, and between 1995 and 2001, Mr. Paulson served in various capacities at Medtronic, Inc. Marc P. Flores, president and chief executive officer of MedicalCV Inc., commented, "We are extremely pleased to have two individuals with the wealth of experience in the medical device industry possessed by Mr. Haimovitch and Mr. Paulson joining our Board. We expect them to play an important role in shaping our strategy as we continue to develop products for the growing atrial fibrillation market." About MedicalCV, Inc. MedicalCV, Inc., a cardiovascular surgery device manufacturer, focuses on the development and introduction of products designed to improve patient outcomes through the early treatment of cardiovascular disorders and disease specifically, products used by cardiac surgeons to ablate cardiac tissue as a potential means to treat atrial fibrillation. The Company's core technology is the ATRILAZE(TM) Surgical Ablation System for use in cardiac tissue ablation procedures in open-heart surgery. The Company acquired this technology in August 2003 and received its FDA 510(k) clearance in November 2004. The ATRILAZE(TM) system is being utilized for concomitant open-heart surgical procedures. The Company's common stock is traded on the OTC Bulletin Board under the symbol "MDCV." For further information on MedicalCV, Inc., please visit http://www.medcvinc.com/. You may register to receive MedicalCV's future press releases and to be added to the Company's distribution list by visiting: http://www.roiny.com/form.php. MedicalCV, Inc. Contact: Investor Relations Contact: John H. Jungbauer ROI Group Associates, Inc. Vice President, Finance & CFO Robert Giordano / Sarah Shepard Phone 651.452.3000 President / Vice President Phone 212.495.0200, ext. 10 / 17 http://www.medcvinc.com/ / http://www.roiny.com/ DATASOURCE: MedicalCV, Inc. CONTACT: John H. Jungbauer, Vice President, Finance & CFO of MedicalCV, Inc., +1-651-452-3000, ; or Investor Relations, Robert Giordano, President, ext. 10, , or Sarah Shepard, Vice President, ext. 17, , both of ROI Group Associates, Inc., +1-212-495-0200 Web site: http://www.medcvinc.com/ http://www.roiny.com/

Copyright